Cox-2 selective inhibitors: A literature review of analgesic efficacy and safety in oral-maxillofacial surgery

Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics

Volumn 97, Issue 2, 2004, Pages 139-146

  Cicconetti, Andrea ^a,b   Bartoli, Adriano ^a   Ripari, Francesca ^a   Ripari, Andrea ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b University of Rome La Sapienza ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; ANTICOAGULANT AGENT; ANTIINFLAMMATORY AGENT; CELECOXIB; CODEINE; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ETORICOXIB; IBUPROFEN; INDOMETACIN; KETOROLAC; LUMIRACOXIB; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OXYCODONE; PARACETAMOL; PARECOXIB; ROFECOXIB; VALDECOXIB;

ABDOMINAL PAIN; ANALGESIA; BIBLIOGRAPHIC DATABASE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DENTAL SURGERY; DENTISTRY; DIARRHEA; DIGESTIVE SYSTEM ULCER; DIZZINESS; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FOOD AND DRUG ADMINISTRATION; FRACTURE HEALING; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HEADACHE; HUMAN; INTESTINE PERFORATION; KIDNEY FUNCTION; MAXILLOFACIAL SURGERY; MEDLINE; NAUSEA; ORAL SURGERY; OSTEOARTHRITIS; POSTOPERATIVE PAIN; RANDOMIZATION; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SOMNOLENCE; THROMBOCYTE AGGREGATION INHIBITION; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WOUND HEALING;

EID: 1242306450     PISSN: 10792104     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tripleo.2003.08.032     Document Type: Review

References (63)

1. Fu J.Y., Masferrer J.L., Seibert K., Raz A., Needleman P. The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem. 265:1990;16737-16740.
2. Pairet M., Engelhardt G. Distinct isoforms (COX-1, COX-2) of cyclooxygenase, possible physiologic and therapeutic implications. Fundam Clin Pharmacol. 10:1996;1-17.
3. Simon A.M., Manigrasso M.B., O'Connor J.P. Cyclooxygenase-2 function is essential for bone fracture healing. J Bone Miner Res. 17:2002;963-976.
4. Komhoff M., Grone H.J., Klein T., Seyberth H.W., Nusing R.M. Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney implication for renal function . Am J Physiol. 272:(4 Pt 2):1997;F460-468.
5. Samad T.A., Moore K.A., Sapirstein A., Billet S., Allchorne A., Poole S., Bonventre J.V., Woolf C.J. Interleukin-1beta-mediated induction of COX-2 in the CNS contributes to inflammatory pain hypersensitivity. Nature. 410:(6827):2001;471-475.
6. Dionne R.A., Gordon S.M., Dubner R. Relationship of prostaglandin E2 to acute pain and analgesia. J Dent Res. 75:(spec issue):1996;137.
7. Bombardier C., Laine L., Reicin A., Shapiro D., Burgos-Vargas R., Davis B., et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. New Engl J Med. 343:2000;1520-1528.
8. Giercksky K.E., Huseby G., Rugstad H.E. Epidemiology of NSAID-related gastrointestinal side effects. Scand J Gastroenterol. 163:(Suppl):1989;3-8.
9. Forbes J.A. Oral surgery. Max M.B., Portenoy R.K., Laska E.M. Advances in pain research and therapy the design of analgesic clinical trials . 1991;347-374 Raven Press, New York.
10. Cooper S.A., Beaver W.T. A model to evaluate mild analgesics in oral surgery outpatients. Clin Pharmacol Ther. 20:1976;241-250.
11. Norholt S.E. Treatment of acute pain following removal of mandibular third molars. Use of the dental pain model in pharmacological research and development of a comparable animal model. Int J Oral Maxillofac Surg. 27:(Suppl 1):1998;1-41.
12. Dionne R.A., Berthold C.W. Therapeutic uses of non-steroidal anti-inflammatory drugs in dentistry. Crit Rev Oral Biol Med. 12:(4):2001;315-330.
13. Weaver A.L. Rofecoxib clinical pharmacology and clinical experience . Clin Ther. 23:(9):2001;1323-1338.
14. Malmstrom K., Daniels S., Kotey P., Seidenberg B.C., Desjardins P.J. Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors, in postoperative dental pain a randomised placebo- and active- comparator controlled clinical trial . Clin Ther. 21:(10):1999;1653-1663.
15. Doyle G., Jayawardena S., Ashraf E., Cooper S.A. Efficacy and tolerability of non-prescription ibuprofen versus celecoxib for dental pain. J Clin Pharmacol. 42:(8):2002;912-919.
16. Khan A.A., Brahim J.S., Rowan J.S., Dionne R.A. In vivo selectivity of a selective cyclooxygenase 2 inhibitor in the oral surgery model. Clin Pharmacol Ther. 72:(1):2002;44-49.
17. Ehrich E.W., Dallob A., De Lepeleire I., Van Hecken A., Riendeau D., Weying Y., et al. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model. Clin Pharmacol Ther. 65:1999;336-347.
18. Malmstrom K., Daniels S., Kotey P., Seidinberg B.C., Desjardins P.J. Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors, in postoperative dental pain a randomized, placebo- and active-comparator- controlled clinical trial . Clin Ther. 21:1999;1653-1663.
19. Morrison B.W., Christensen S., Yuan W., Brown J., Arnlani S., Seidenberg B. Analgesic efficacy of the cyclooxygenase-2 specific inhibitor rofecoxib in post dental surgery pain a randomized, controlled trial . Clin Ther. 21:1999;943-953.
20. Fricke J., Morrison B.W., Fite S., Sandler M., Yuan W., Howard C., et al. MK966 versus naproxen sodium 550 mg in postsurgical dental pain. [abstract no.PI-7] Clin Pharmacol Ther. 65:1999;119.
21. Brown J., Morrison B.W., Christensen S., Dunkley V., Sandler M., Turpin M., et al. MK-0966 50 mg versus ibuprofen 400 mg in post-surgical dental pain. [abstract no.PI-4] Clin Pharmacol Ther. 65:(2):1999;118.
22. Chang D.J., Desjardins P.J., Chen E., Polis A.B., McAvoy M., Mockoviak S.H., et al. Comparison of the analgesic efficacy of rofecoxib and enteric-coated diclofenac sodium in the treatment of postoperative dental pain a randomized, placebo-controlled clinical trial . Clin Ther. 24:2002;490-503.
23. Chang D.J., Fricke J.R., Bird S.R., Bohidar N.R., Dobbins T.W., Geba G.P. Rofocoxib versus codeine/acetaminophen in postoperative dental pain a double-blind, randomized, placebo- and active comparator-controlled clinical trial . Clin Ther. 23:2001;1446-1455.
24. Morrison B.W., Fricke J., Brown J., Yuan W., Kotey P., Melish D. The optimal analgesic dose of rofecoxib overview of six randomized controlled trials . J Am Dent Assoc. 131:2000;1729-1737.
25. Jeske A.H. Selecting new drugs for pain control. Evidence-based decisions or clinical impressions? J Am Dent Assoc. 133:(8):2002;1052-1056.
26. Buvanendran A., Luk P., Kroin J.S., Rodger I.V., McCarthy R.J. Central nervous system penetration of oral rofecoxib, a selective cyclooxygenase-2 inhibitor, in rats. Anesthesiology. 95:2001;A868.
27. MEDLINEplus. Rofecoxib to prevent pain after third molar extraction (NIDCR). Available at: http://www.ClinicalTrials.gov. Accessed August 2002.
28. Cryer B., Feldman M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med. 104:1998;413-421.
29. Dahl V., Raeder J.C. Non-opioid postoperative analgesia. Acta Anaesthesiol Scand. 44:2000;1191-1203.
30. Fricke J., Varkalis J., Zwillich S., Adler R., Forester E., Recker D.P., et al. Valdecoxib is more efficacious than rofecoxib in relieving pain associated with oral surgery. Am J Ther. 9:(2):2002;89-97.
31. Daniels S.E., Desjardins P.J., Talwalker S., Recker D.P., Verburg K.M. The analgesic efficacy of valdecoxib vs oxicodone/acetaminophen after oral surgery. J Am Dent Assoc. 133:(5):2002;611-621.
32. Ormrod D., Wellington K., Wagstaff A.J. Valdecoxib. Drugs. 62:(14):2002;2059-2071. ; discussion 2072-3.
33. Desjardins P.J., Shu V.S., Recker D.P., Verburg K.M., Woolf C.J. A single preoperative oral dose of valdecoxib, a new cyclooxygenase-2 specific inhibitor, relieves post-oral surgery or bunionectomy pain. Anesthesiology. 97:(3):2002;565-573.
34. Cheer S.M., Goa K.L. Parecoxib (parecoxib sodium). Drugs. 61:(8):2001;1133-1141.
35. Jain K.K. Evaluation of intravenous parecoxib for the relief of acute post-surgical pain. Expert Opin Invest Drug. 9:(11):2000;2717-2723.
36. Desjardins P.J., Grossman E.H., Kuss M.E., Talwalker S., Dhadda S., Baum D., et al. The injectable cyclooxygenase-2-specific inhibitor parecoxib sodium has analgesic efficacy when administered preoperatively. Anesth Analg. 93:(3):2001;721-727.
37. Riendeau D., Percival M.D., Brideau C., Charleson S., Dube D., Ethier D., et al. Etoricoxib (MK-0663) preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2 . J Pharmacol Exp Ther. 296:(2):2001;558-566.
38. Cochrane D.J., Jarvis B., Keating G.M. Etoricoxib. Drugs. 62:(18):2002;2637-2651.
39. Stichtenoth D.O., Frolich J.C. The second generation of COX-2 inhibitors what advantages do the newest offer? Drugs. 63:(1):2003;33-45.
40. Brune K., Neubert A. Pharmacokinetic and pharmacodynamic aspects of the ideal COX-2 inhibitor a pharmacologist's perspective . Clin Exp Rheumatol. 19: (6 Suppl 25):2001;S51-57.
41. Scheiman J.M. Outcomes studies of the gastrointestinal safety of cyclooxygenase-2 inhibitors. Cleve Clin J Med. 69:(Suppl 1):2002;SI40-46.
42. Harris RC Jr. Cyclooxygenase-2 inhibition and renal physiology. Am J Cardiol 2002 Mar 21;89(6A):10D-7D.
43. US Food and Drug Administration. Celebrex capsules (celecoxib) NDA 20-998/S-009 Medical Officer Review. Available at: http://www.fda.gov/ohrms/ dockets/ac/01/briefing/3677b1.htm. Accessed June 2002.
44. US Food and Drug Administration. NDA 21-042, s007, Vioxx gastrointestinal safety- Medical Officer Review. Available at: http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b2-03-med.doc. Accessed June 2002.
45. Schafer A.I. Effects of nonsteroidal anti-inflammatory therapy on platelets. Am J Med. 106:(Suppl 5B):1999;25S-36S.
46. Leese P.T., Talwalker S., Kent J.D., Recker D.P. Valdecoxib does not impair platelet function. Am J Emerg Med. 20:(4):2002;275-281.
47. Parnham M.J. Selective COX-2 inhibitors. Drug News Perspect. 10:1997;182-187.
48. Ouellet M., Riendeau D., Percival M.D. A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin. Proc Natl Acad Sci U S A. 98:(25):2001;14583-14588.
49. Mukheljee D., Nissen S.E., Topol E.J. Risk of cariovascular events associated with selective COX-2 inhihitors. JAMA. 286:2001;954-959.
50. Fitzgerald G.A. Cardiovascular pharmacology of nonselective nonsteroidal anti-inflammatory drugs and coxibs clinical considerations . Am J Cardiol. 89:(6A):2002;26D-32D.
51. Altman R.D., Latta L.L., Keer R., Renfree K., Hornicek F.J., Banovac K. Effect of nonsteroidal anti-inflammatory drugs on fracture healing, a laboratory study in rats. J Orthop Trauma. 9:1995;392-400.
52. Proper S.A., Fenske N.A., Burnett S.M., Luria L.W. Compromised wound repair caused by perioperative use of ibuprofen. J Am Acad Dermatol. 18:(5 pt 2):1988;1173-1179.
53. Quirinia A., Viidik A. Diclofenac and indomethacin influence the healing of normal and ischaemic incisional wounds in skin. Scand J Plast Reconstr Surg Hand Surg. 31:1997;213-219.
54. Dvivedi S., Tiwari S.M., Sharm A. Effect of ibuprofen and diclofenac sodium on experimental would healing. Indian J Exp Biol. 35:1997;1243-1245.
55. Scott L.J., Lamb H.M. Rofecoxib. Drugs. 58:(3):1999;499-505. discussion 506-7.
56. Garnett W.R. Clinical implications of drug interactions with coxibs. Pharmacotherapy. 21:(10):2001;1223-1232.
57. Stevenson D.D., Simon R.A. Lack of cross-reactivity between rofecoxib and aspirin in aspirin-sensitive patients with asthma. J Allergy Clin Immunol. 108:(1):2001;47-51.
58. Medsafe Editorial Team. Interaction between COX-2 inhibitors and Warfarin. Available at: http://www.medsafe.govt.nz/Profs/Puarticles/cox2warf. htm. Accessed June 2002.
59. McMurray R.W., Hardy K.J. COX-2 inhibitors today and tomorrow . Am J Med Sci. 323:(4):2002;181-189.
60. Laine L., Bombardier C., Reicin A., Howkey C., Watson D.J., Ramey D.R., et al. Gastrointestinal (GI) co-therapy, procedures, and hospitalizations in a GI outcomes study of rofecoxib vs naproxen in rheumatoid arthritis. [abstract] Am J Gastroenterol. 95:2000;2633.
61. Fendrick A.M. Developing an economic rationale for the use of selective COX-2 inhibitors for patients at risk for NSAID gastropathy. Cleve Clin J Med. 69:(Suppl 1):2002;SI59-64.
62. Edmonds J.P., Day R.O., Bertouch J.V. The road to consensus considerations for the safe use and prescribing of COX-2-specific inhibitors . Med J Aust. 176:(7):2002;332-334.
63. MEDLINEplus. Study of etanercept and celecoxib to treat temporomandibular disorders (NIDCR). Available at: http://www.ClinicalTrials. gov. Accessed August 2002.